## Annamaria Colao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/950476/publications.pdf

Version: 2024-02-01

433 papers

22,895 citations

76 h-index 125 g-index

446 all docs

446 docs citations

times ranked

446

17907 citing authors

#	Article	IF	CITATIONS
1	Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocrine Reviews, 2004, 25, 102-152.	20.1	1,093
2	Advances in the Treatment of Prolactinomas. Endocrine Reviews, 2006, 27, 485-534.	20.1	707
3	A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease. New England Journal of Medicine, 2012, 366, 914-924.	27.0	550
4	Nutritional recommendations for CoVID-19 quarantine. European Journal of Clinical Nutrition, 2020, 74, 850-851.	2.9	353
5	Persistence of Increased Cardiovascular Risk in Patients with Cushing's Disease after Five Years of Successful Cure. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2664-2672.	3.6	344
6	Growth hormone and the heart. Clinical Endocrinology, 2001, 54, 137-154.	2.4	328
7	Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 791-799.	3.6	321
8	Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia. New England Journal of Medicine, 2003, 349, 2023-2033.	27.0	310
9	Early Impairment of Endothelial Structure and Function in Young Normal-Weight Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4588-4593.	3.6	310
10	The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 223-230.	3.6	297
11	The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3696-3701.	3.6	250
12	Gut microbiota: a new path to treat obesity. International Journal of Obesity Supplements, 2019, 9, 10-19.	12.6	239
13	Resistance to Somatostatin Analogs in Acromegaly. Endocrine Reviews, 2011, 32, 247-271.	20.1	220
14	The Increase of Leukocytes as a New Putative Marker of Low-Grade Chronic Inflammation and Early Cardiovascular Risk in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2-5.	3.6	212
15	Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. European Journal of Endocrinology, 2003, 148, 325-331.	3.7	203
16	Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1704-1711.	3.6	200
17	Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Human Reproduction, 2008, 23, 642-650.	0.9	197
18	Commentary: Obesity: The "Achilles heel―for COVID-19?. Metabolism: Clinical and Experimental, 2020, 108, 154251.	3.4	182

#	Article	IF	CITATIONS
19	Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 85-92.	3.6	178
20	The GH–IGFâ€I axis and the cardiovascular system: clinical implications. Clinical Endocrinology, 2008, 69, 347-358.	2.4	178
21	Beneficial Effects of a Three-Month Structured Exercise Training Program on Cardiopulmonary Functional Capacity in Young Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1379-1384.	3.6	172
22	Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 195-205.	5.7	170
23	Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). Journal of Endocrinological Investigation, 2019, 42, 1365-1386.	3.3	167
24	Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1919-1924.	3.6	166
25	Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. Nutrients, 2018, 10, 1971.	4.1	164
26	Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS). Nutrients, 2019, 11, 2278.	4.1	162
27	Systemic Hypertension and Impaired Glucose Tolerance Are Independently Correlated to the Severity of the Acromegalic Cardiomyopathy $<$ sup $<$ 1 $<$ 1 sup $<$ 1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 193-199.	3.6	154
28	Increased Prevalence of Tricuspid Regurgitation in Patients with Prolactinomas Chronically Treated with Cabergoline. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3777-3784.	3.6	154
29	Medical therapy for clinically non-functioning pituitary adenomas. Endocrine-Related Cancer, 2008, 15, 905-915.	3.1	152
30	Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology, 2006, 154, 467-477.	3.7	148
31	Medical treatment of prolactinomas. Nature Reviews Endocrinology, 2011, 7, 267-278.	9.6	136
32	Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 335-346.	5.7	134
33	Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3746-3756.	3.6	132
34	The prolactinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 575-596.	4.7	130
35	Improvement in Endothelial Structure and Function after Metformin Treatment in Young Normal-Weight Women with Polycystic Ovary Syndrome: Results of a 6-Month Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6072-6076.	3.6	129
36	Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. European Journal of Endocrinology, 2001, 144, 499-507.	3.7	128

3

#	Article	IF	CITATIONS
37	Prediction of efficacy of octreotide therapy in patients with acromegaly Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2356-2362.	3.6	126
38	Obesity and sleep disturbance: the chicken or the egg?. Critical Reviews in Food Science and Nutrition, 2019, 59, 2158-2165.	10.3	125
39	Pregnancy outcomes following cabergoline treatment: extended results from a 12â€year observational study. Clinical Endocrinology, 2008, 68, 66-71.	2.4	120
40	High Prevalence of Cardiac Valve Disease in Acromegaly: An Observational, Analytical, Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3196-3201.	3.6	119
41	Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetologica, 2009, 46, 85-95.	2.5	119
42	Predictors of Tumor Shrinkage after Primary Therapy with Somatostatin Analogs in Acromegaly: A Prospective Study in 99 Patients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2112-2118.	3.6	116
43	Low vitamin D status and obesity: Role of nutritionist. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 215-225.	5.7	116
44	Dopamine receptor agonists for treating prolactinomas. Expert Opinion on Investigational Drugs, 2002, 11, 787-800.	4.1	112
45	Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?. Journal of Translational Medicine, 2015, 13, 18.	4.4	112
46	European Guidelines for Obesity Management in Adults with a Very Low-Calorie Ketogenic Diet: A Systematic Review and Meta-Analysis. Obesity Facts, 2021, 14, 222-245.	3.4	112
47	Octreotide LAR <i>&gt;vs.</i> surgery in newly diagnosed patients with acromegaly: a randomized, open″abel, multicentre study. Clinical Endocrinology, 2009, 70, 757-768.	2.4	108
48	Vitamin D and chronic diseases: the current state of the art. Archives of Toxicology, 2017, 91, 97-107.	4.2	108
49	The Cardiovascular Risk of GH-Deficient Adolescents. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3650-3655.	3.6	104
50	Spleen: A new role for an old player?. World Journal of Gastroenterology, 2011, 17, 3776.	3.3	104
51	The management of very low-calorie ketogenic diet in obesity outpatient clinic: a practical guide. Journal of Translational Medicine, 2019, 17, 356.	4.4	102
52	Increased arterial intimaâ€media thickness by Bâ€M mode echodoppler ultrasonography in acromegaly. Clinical Endocrinology, 2001, 54, 515-524.	2.4	101
53	The Severity of Growth Hormone Deficiency Correlates with the Severity of Cardiac Impairment in 100 Adult Patients with Hypopituitarism: An Observational, Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5998-6004.	3.6	101
54	The Cardiovascular Risk of Adult GH Deficiency (GHD) Improved after GH Replacement and Worsened in Untreated GHD: A 12-Month Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1088-1093.	3.6	99

#	Article	IF	CITATIONS
55	Reversal of acromegalic cardiomyopathy in young but not in middleâ€aged patients after 12Âmonths of treatment with the depot longâ€acting somatostatin analogue octreotide. Clinical Endocrinology, 2003, 58, 169-176.	2.4	99
56	Rethinking the role of the school after COVID-19. Lancet Public Health, The, 2020, 5, e370.	10.0	99
57	Searching for SARS-COV-2 on Particulate Matter: A Possible Early Indicator of COVID-19 Epidemic Recurrence. International Journal of Environmental Research and Public Health, 2020, 17, 2986.	2.6	99
58	Shedding new light on female fertility: The role of vitamin D. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 273-283.	5.7	98
59	Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clinical Endocrinology, 2007, 67, 426-433.	2.4	97
60	Vitamin D and cardiovascular disease: From atherosclerosis to myocardial infarction and stroke. International Journal of Cardiology, 2017, 230, 577-584.	1.7	96
61	The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1277-1282.	3.6	93
62	Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. European Journal of Endocrinology, 2008, 159, 389-397.	3.7	93
63	Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clinical Endocrinology, 2000, 52, 319-327.	2.4	91
64	Intracellular Inactivation of Thyroid Hormone Is a Survival Mechanism for Muscle Stem Cell Proliferation and Lineage Progression. Cell Metabolism, 2014, 20, 1038-1048.	16.2	91
65	Trimethylamine N-oxide, Mediterranean diet, and nutrition in healthy, normal-weight adults: also a matter of sex?. Nutrition, 2019, 62, 7-17.	2.4	91
66	Does Sars-Cov-2 threaten our dreams? Effect of quarantine on sleep quality and body mass index. Journal of Translational Medicine, 2020, 18, 318.	4.4	91
67	Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. Nutrition Research Reviews, 2018, 31, 291-301.	4.1	90
68	Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic <i>lamina propria</i> in acromegaly. Clinical Endocrinology, 1997, 47, 23-28.	2.4	89
69	Sex Differences of Vitamin D Status across BMI Classes: An Observational Prospective Cohort Study. Nutrients, 2019, 11, 3034.	4.1	86
70	Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?. Neuroendocrinology, 2021, 111, 1066-1085.	2.5	85
71	Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3001-3008.	3.6	84
72	Nutrition and immune system: from the Mediterranean diet to dietary supplementary through the microbiota. Critical Reviews in Food Science and Nutrition, 2021, 61, 3066-3090.	10.3	83

#	Article	IF	CITATIONS
73	Cardiovascular Consequences of Early-Onset Growth Hormone Excess. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3097-3104.	3.6	82
74	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary, 1999, 1, 115-120.	2.9	81
75	Vitamin D testing: advantages and limits of the current assays. European Journal of Clinical Nutrition, 2020, 74, 231-247.	2.9	81
76	The heart: an end-organ of GH action. European Journal of Endocrinology, 2004, 151 Suppl 1, S93-101.	3.7	80
77	Bisphenol <scp>A</scp> in polycystic ovary syndrome and its association with liver–spleen axis. Clinical Endocrinology, 2013, 78, 447-453.	2.4	79
78	Long period fiber grating nano-optrode for cancer biomarker detection. Biosensors and Bioelectronics, 2016, 80, 590-600.	10.1	79
79	Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2639-2646.	3.6	78
80	The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology, 2000, 53, 53-60.	2.4	77
81	Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly. European Journal of Endocrinology, 2007, 157, 579-587.	3.7	77
82	Vitamin D and pancreas: The role of sunshine vitamin in the pathogenesis of diabetes mellitus and pancreatic cancer. Critical Reviews in Food Science and Nutrition, 2017, 57, 3472-3488.	10.3	77
83	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine, 2017, 58, 349-359.	2.3	77
84	Nutrition, inflammation and liver-spleen axis. Critical Reviews in Food Science and Nutrition, 2018, 58, 3141-3158.	10.3	74
85	Sleep Quality in Obesity: Does Adherence to the Mediterranean Diet Matter?. Nutrients, 2020, 12, 1364.	4.1	74
86	Italian doctors call for protecting healthcare workers and boosting community surveillance during covid-19 outbreak. BMJ, The, 2020, 368, m1254.	6.0	73
87	Beginning to end: Cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Hormone and IGF Research, 2006, 16, 41-48.	1.1	72
88	Vitamin D and thyroid disease: to D or not to D?. European Journal of Clinical Nutrition, 2015, 69, 291-296.	2.9	71
89	The lullaby of the sun: the role of vitamin D in sleep disturbance. Sleep Medicine, 2019, 54, 262-265.	1.6	71
90	Cardiopulmonary Impairment in Young Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2967-2971.	3.6	70

#	Article	IF	CITATIONS
91	Role of Nutrition and Adherence to the Mediterranean Diet in the Multidisciplinary Approach of Hidradenitis Suppurativa: Evaluation of Nutritional Status and Its Association with Severity of Disease. Nutrients, 2019, 11, 57.	4.1	70
92	First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clinical Endocrinology, 2006, 64, 342-351.	2.4	69
93	Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. European Journal of Endocrinology, 2011, 165, 713-721.	3.7	69
94	Chronotype and Adherence to the Mediterranean Diet in Obesity: Results from the Opera Prevention Project. Nutrients, 2020, 12, 1354.	4.1	68
95	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1986-1991.	3.6	67
96	Cabergoline. Expert Opinion on Pharmacotherapy, 2000, 1, 555-574.	1.8	67
97	Sleep Apnea, Obesity, and Disturbed Glucose Homeostasis: Epidemiologic Evidence, Biologic Insights, and Therapeutic Strategies. Current Obesity Reports, 2020, 9, 30-38.	8.4	67
98	Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. Reproductive BioMedicine Online, 2004, 9, 505-510.	2.4	66
99	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. European Journal of Endocrinology, 2017, 176, 453-461.	3.7	66
100	Human exposure to bisphenol AF and diethylhexylphthalate increases susceptibility to develop differentiated thyroid cancer in patients with thyroid nodules. Chemosphere, 2019, 218, 885-894.	8.2	66
101	Low glycaemic diet and metformin therapy: a new approach in male subjects with acne resistant to common treatments. Clinical and Experimental Dermatology, 2016, 41, 38-42.	1.3	65
102	Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. International Journal of Obesity, 2022, 46, 449-465.	3.4	65
103	Gender- and age-related differences in the endocrine parameters of acromegaly. Journal of Endocrinological Investigation, 2002, 25, 532-538.	3.3	64
104	Significant tumour shrinkage after 12Âmonths of lanreotide Autogelâ€120Âmg treatment given firstâ€line in acromegaly. Clinical Endocrinology, 2009, 71, 237-245.	2.4	64
105	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. Journal of Endocrinological Investigation, 2012, 35, 817-23.	3.3	64
106	Treatment of prolactinomas. Annals of Medicine, 1998, 30, 452-459.	3.8	63
107	Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. European Journal of Endocrinology, 2002, 146, 303-309.	3.7	63
108	Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. Journal of Endocrinological Investigation, 2005, 28, 440-448.	3.3	63

#	Article	IF	Citations
109	A Reappraisal of Diagnosing GH Deficiency in Adults: Role of Gender, Age, Waist Circumference, and Body Mass Index. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4414-4422.	3.6	63
110	Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. Journal of Translational Medicine, 2015, 13, 303.	4.4	63
111	Low serum vitamin D-status, air pollution and obesity: A dangerous liaison. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 207-214.	5.7	63
112	Acromegaly is associated with increased cancer risk: a survey in Italy. Endocrine-Related Cancer, 2017, 24, 495-504.	3.1	61
113	Mediterranean Diet and Phase Angle in a Sample of Adult Population: Results of a Pilot Study. Nutrients, 2017, 9, 151.	4.1	61
114	Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. Nutrients, 2018, 10, 1854.	4.1	61
115	Effect of Cabergoline on Metabolism in Prolactinomas. Neuroendocrinology, 2013, 98, 299-310.	2.5	60
116	Phase Angle: A Possible Biomarker to Quantify Inflammation in Subjects with Obesity and 25(OH)D Deficiency. Nutrients, 2019, 11, 1747.	4.1	60
117	Cardiovascular risk in women with polycystic ovary syndrome. Fertility and Sterility, 2006, 86, S20-S21.	1.0	58
118	Bioelectrical phase angle and psoriasis: a novel association with psoriasis severity, quality of life and metabolic syndrome. Journal of Translational Medicine, 2016, 14, 130.	4.4	58
119	Prader- Willi syndrome: An uptodate on endocrine and metabolic complications. Reviews in Endocrine and Metabolic Disorders, 2019, 20, 239-250.	5.7	58
120	Recombinant Growth Hormone (GH) Therapy in GH-Deficient Adults: A Long-Term Controlled Study on DailyVersusThrice Weekly Injections. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3720-3725.	3.6	57
121	Growth Hormone Treatment on Atherosclerosis: Results of a 5-Year Open, Prospective, Controlled Study in Male Patients with Severe Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3416-3424.	3.6	57
122	Therapy of aggressive pituitary tumors. Expert Opinion on Pharmacotherapy, 2011, 12, 1561-1570.	1.8	57
123	Growth Hormone Replacement Delays the Progression of Chronic Heart Failure Combined With Growth Hormone Deficiency. JACC: Heart Failure, 2013, 1, 325-330.	4.1	57
124	Lipid profile in nonobese pregnant women with polycystic ovary syndrome: A prospective controlled clinical study. Steroids, 2014, 88, 36-43.	1.8	57
125	Nutritional status and follicular-derived thyroid cancer: An update. Critical Reviews in Food Science and Nutrition, 2021, 61, 25-59.	10.3	57
126	The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clinical Endocrinology, 2006, 64, 307-313.	2.4	56

#	Article	IF	CITATIONS
127	The Association of Fasting Insulin Concentrations and Colonic Neoplasms in Acromegaly: A Colonoscopy-Based Study in 210 Patients. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3854-3860.	3.6	56
128	Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. European Journal of Endocrinology, 2003, 148, 31-38.	3.7	55
129	Short-Term Effects of Growth Hormone (GH) Treatment or Deprivation on Cardiovascular Risk Parameters and Intima-Media Thickness at Carotid Arteries in Patients with Severe GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2056-2062.	3.6	55
130	Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 200-210.	2.8	55
131	Obesogenic endocrine disruptors and obesity: myths and truths. Archives of Toxicology, 2017, 91, 3469-3475.	4.2	55
132	Evaluation of <i>BRAF</i> , <i>RAS</i> , <i>RET/PTC</i> , and <i>PAX8/PPARg</i> alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7â€gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy. Cancer Cytopathology, 2020, 128, 107-118.	2.4	55
133	Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells. Scientific World Journal, The, 2014, 2014, 1-13.	2.1	54
134	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology, 2018, 155, 479-489.e7.	1.3	54
135	A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). Nutrients, 2019, 11, 1310.	4.1	54
136	An Italian Survey on Dietary Habits and Changes during the COVID-19 Lockdown. Nutrients, 2021, 13, 1197.	4.1	54
137	Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. Journal of Translational Medicine, 2011, 9, 136.	4.4	53
138	Oral contraceptives <i>versus</i> physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial. Clinical Endocrinology, 2016, 85, 764-771.	2.4	53
139	Pegvisomant in acromegaly: an update. Journal of Endocrinological Investigation, 2017, 40, 577-589.	3.3	53
140	Obesity and breast cancer in premenopausal women: Current evidence and future perspectives. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 230, 217-221.	1.1	53
141	Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactinâ€secreting and clinically nonâ€functioning pituitary adenomas: predictive value of pituitary scintigraphy with ⟨sup⟩123⟨/sup⟩lâ€methoxybenzamide. Clinical Endocrinology, 2000, 52, 437-445.	2.4	52
142	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clinical Endocrinology, 2000, 53, 13-19.	2.4	52
143	Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2907-2914.	3.6	52
144	Impact of Somatostatin AnalogsVersusSurgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 528-537.	3.6	51

#	Article	IF	Citations
145	Medical therapy of pituitary adenomas: Effects on tumor shrinkage. Reviews in Endocrine and Metabolic Disorders, 2009, 10, 111-123.	5.7	51
146	Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurgical Review, 2017, 40, 105-114.	2.4	51
147	Nutritional and Environmental Factors in Thyroid Carcinogenesis. International Journal of Environmental Research and Public Health, 2018, 15, 1735.	2.6	50
148	How much does obesity affect the male reproductive function?. International Journal of Obesity Supplements, 2019, 9, 50-64.	12.6	50
149	From gut microbiota dysfunction to obesity: could short-chain fatty acids stop this dangerous course?. Hormones, 2019, 18, 245-250.	1.9	50
150	Coffee consumption, metabolic syndrome and clinical severity of psoriasis: good or bad stuff?. Archives of Toxicology, 2018, 92, 1831-1845.	4.2	49
151	Anti-Inflammatory Nutrients and Obesity-Associated Metabolic-Inflammation: State of the Art and Future Direction. Nutrients, 2022, 14, 1137.	4.1	49
152	Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocrine Disorders, 2010, 10, 10.	2.2	48
153	Cardiovascular risk in adult hypopituitaric patients with growth hormone deficiency: is there a role for vitamin D?. Endocrine, 2016, 52, 111-119.	2.3	48
154	Preliminary results demonstrating the impact of Mediterranean diet on bone health. Journal of Translational Medicine, 2017, 15, 81.	4.4	48
155	Adherence to the Mediterranean Diet and Circulating Levels of Sirtuin 4 in Obese Patients: A Novel Association. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.	4.0	48
156	Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary, 2012, 15, 50-58.	2.9	47
157	Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine, 2016, 52, 488-494.	2.3	47
158	Influence of nutrition on somatotropic axis: Milk consumption inÂadult individuals with moderate-severe obesity. Clinical Nutrition, 2017, 36, 293-301.	5.0	47
159	Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. Metabolism: Clinical and Experimental, 2018, 78, 141-154.	3.4	47
160	Does a Gender-Related Effect of Growth Hormone (CH) Replacement Exist on Cardiovascular Risk Factors, Cardiac Morphology, and Performance and Atherosclerosis? Results of a Two-Year Open, Prospective Study in Young Adult Men and Women with Severe GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5146-5155.	3.6	45
161	A Community-Based, Technology-Supported Health Service for Detecting and Preventing Frailty among Older Adults: A Participatory Design Development Process. Journal of Aging Research, 2015, 2015, 1-9.	0.9	45
162	Vitamin D and Sleep Regulation: Is there a Role for Vitamin D?. Current Pharmaceutical Design, 2020, 26, 2492-2496.	1.9	45

#	Article	IF	CITATIONS
163	Insulinâ€like growth factorâ€l deficiency determines increased intima–media thickness at common carotid arteries in adult patients with growth hormone deficiency. Clinical Endocrinology, 2004, 61, 360-366.	2.4	44
164	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. Annals of Surgery, 2020, 271, 527-533.	4.2	44
165	First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment) Tj ETQq1 Endocrinological Investigation, 2006, 29, 1017-1020.	1 0.784314 3.3	rgBT /Over 43
166	Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clinical Endocrinology, 2006, 65, 250-256.	2.4	42
167	Phase Angle as an Easy Diagnostic Tool of Meta-Inflammation for the Nutritionist. Nutrients, 2021, 13, 1446.	4.1	42
168	The role of outdoor and indoor air quality in the spread of SARS-CoV-2: Overview and recommendations by the research group on COVID-19 and particulate matter (RESCOP commission). Environmental Research, 2022, 211, 113038.	7.5	42
169	Common Carotid Intima-Media Thickness in Growth Hormone (GH)-Deficient Adolescents: A Prospective Study after GH Withdrawal and Restarting GH Replacement. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2659-2665.	3.6	41
170	Vitamin D in obesity and obesity-related diseases: an overview. Minerva Endocrinology, 2021, 46, 177-192.	1.1	41
171	Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clinical Endocrinology, 2007, 67, 845-852.	2.4	40
172	Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Endocrine, 2016, 52, 495-506.	2.3	40
173	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine, 2016, 51, 131-139.	2.3	40
174	The management of neuroendocrine tumours: A nutritional viewpoint. Critical Reviews in Food Science and Nutrition, 2019, 59, 1046-1057.	10.3	40
175	From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. International Journal of Obesity Supplements, 2020, 10, 35-49.	12.6	40
176	Somatostatin Receptor Subtypes in Human Thymoma and Inhibition of Cell Proliferation by Octreotide in Vitro. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1719-1726.	3.6	40
177	Self-Assessment of Adherence to Medication: A Case Study in Campania Region Community-Dwelling Population. Journal of Aging Research, 2015, 2015, 1-6.	0.9	39
178	A rare rarity: Neuroendocrine tumor of the esophagus. Critical Reviews in Oncology/Hematology, 2019, 137, 92-107.	4.4	39
179	Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors & Centimeters. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 78-84.	3.6	39
180	Could ketogenic diet "starve―cancer? Emerging evidence. Critical Reviews in Food Science and Nutrition, 2022, 62, 1800-1821.	10.3	39

#	Article	IF	Citations
181	The Natural History of Partial Growth Hormone Deficiency in Adults: A Prospective Study on the Cardiovascular Risk and Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2191-2200.	3.6	38
182	The treatment of hyperinsulinemic hypoglycaemia in adults: an update. Journal of Endocrinological Investigation, 2017, 40, 9-20.	3.3	38
183	Nutrition and neuroendocrine tumors: An update of the literature. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 159-167.	5.7	38
184	Breast cancer prevention in premenopausal women: role of the Mediterranean diet and its components. Nutrition Research Reviews, 2020, 33, 19-32.	4.1	38
185	GH and IGF†excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clinical Endocrinology, 2008, 69, 613-620.	2.4	37
186	Patient empowerment and the Mediterranean diet as a possible tool to tackle prediabetes associated with overweight or obesity: a pilot study. Hormones, 2019, 18, 75-84.	1.9	37
187	Somatostatin Analogs in Treatment of Non-Growth Hormone-Secreting Pituitary Adenomas. Endocrine, 2003, 20, 279-284.	2.2	36
188	RAPID AND LONG-LASTING SUPPRESSION OF PROLACTIN SECRETION AND SHRINKAGE OF PROLACTINOMAS AFTER INJECTION OF LONG-ACTING REPEATABLE FORM OF BROMOCRIPTINE (PARLODEL LAR). Clinical Endocrinology, 1990, 33, 161-170.	2.4	35
189	Pegvisomant in acromegaly: Why, when, how. Journal of Endocrinological Investigation, 2007, 30, 693-699.	3.3	35
190	Nutrigeneticsâ€"personalized nutrition in obesity and cardiovascular diseases. International Journal of Obesity Supplements, 2020, 10, 1-13.	12.6	34
191	Vitamin D: A Role Also in Long COVID-19?. Nutrients, 2022, 14, 1625.	4.1	34
192	Failure of long-term therapy with sodium valproate in Cushing's disease. Journal of Endocrinological Investigation, 1997, 20, 387-392.	3.3	33
193	Mediterranean diet as medical prescription in menopausal women with obesity: a practical guide for nutritionists. Critical Reviews in Food Science and Nutrition, 2021, 61, 1201-1211.	10.3	33
194	The impact of obesity on immune response to infection: Plausible mechanisms and outcomes. Obesity Reviews, 2021, 22, e13216.	6.5	33
195	Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 807-813.	3.6	33
196	Metabolically Healthy Obesity (MHO) vs. Metabolically Unhealthy Obesity (MUO) Phenotypes in PCOS: Association with Endocrine-Metabolic Profile, Adherence to the Mediterranean Diet, and Body Composition. Nutrients, 2021, 13, 3925.	4.1	33
197	Growth Hormone-Secreting Tumor Shrinkage after 3 Months of Octreotide-Long-Acting Release Therapy Predicts the Response at 12 Months. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3436-3442.	3.6	32
198	Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). European Journal of Endocrinology, 2014, 171, 263-273.	3.7	32

#	Article	IF	Citations
199	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. Digestive and Liver Disease, 2019, 51, 1456-1460.	0.9	32
200	Very low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: an update for dermatologists and nutritionists. Critical Reviews in Food Science and Nutrition, 2022, 62, 398-414.	10.3	32
201	Influence of the Mediterranean Diet on 25-Hydroxyvitamin D Levels in Adults. Nutrients, 2020, 12, 1439.	4.1	32
202	Obesity and Thyroid Cancer Risk: An Update. International Journal of Environmental Research and Public Health, 2022, 19, 1116.	2.6	32
203	Spine abnormalities and damage in patients cured from Cushing's disease. Pituitary, 2001, 4, 153-161.	2.9	31
204	Medical consequences of acromegaly: What are the effects of biochemical control?. Reviews in Endocrine and Metabolic Disorders, 2008, 9, 21-31.	5.7	31
205	Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas. Neuroendocrinology, 2015, 101, 66-81.	2.5	31
206	Preliminary data on the relationship between circulating levels of Sirtuin 4, anthropometric and metabolic parameters in obese subjects according to growth hormone/insulin-like growth factor-1 status. Growth Hormone and IGF Research, 2015, 25, 28-33.	1.1	30
207	The evolving field of kinase inhibitors in thyroid cancer. Critical Reviews in Oncology/Hematology, 2015, 93, 60-73.	4.4	30
208	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine, 2017, 56, 633-638.	2.3	30
209	The effects of hyperprolactinemia and its control on metabolic diseases. Expert Review of Endocrinology and Metabolism, 2018, 13, 99-106.	2.4	30
210	Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any?. Cancer Treatment Reviews, 2018, 67, 1-9.	7.7	30
211	Serum IGF-1 is associated with cognitive functions in early, drug-naÃ⁻ve Parkinson's disease. PLoS ONE, 2017, 12, e0186508.	2.5	30
212	Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia. Endocrine Connections, 2020, 9, 144-153.	1.9	30
213	Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget, 2016, 7, 5538-5547.	1.8	30
214	Effect of Growth Hormone (GH) and/or Testosterone Replacement on the Prostate in GH-Deficient Adult Patients. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 88-94.	3.6	29
215	Adrenocortical tumors and insulin resistance: What is the first step?. International Journal of Cancer, 2016, 138, 2785-2794.	5.1	29
216	The safety of available treatments options for neuroendocrine tumors. Expert Opinion on Drug Safety, 2017, 16, 1149-1161.	2.4	29

#	Article	IF	Citations
217	Animal models of medullary thyroid cancer: state of the art and view to the future. Endocrine-Related Cancer, 2017, 24, R1-R12.	3.1	29
218	Phtalates: new cardiovascular health disruptors?. Archives of Toxicology, 2017, 91, 1513-1517.	4.2	29
219	PCOS and nutritional approaches: Differences between lean and obese phenotype. Metabolism Open, 2021, 12, 100123.	2.9	29
220	From Gut Microbiota through Low-Grade Inflammation to Obesity: Key Players and Potential Targets. Nutrients, 2022, 14, 2103.	4.1	29
221	Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome. Clinical Endocrinology, 2007, 66, 714-722.	2.4	28
222	No Greater Incidence or Worsening of Cardiac Valve Regurgitation with Somatostatin Analog Treatment of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2243-2248.	3.6	28
223	Somatostatin Analogues: Treatment of Pituitary and Neuroendocrine Tumors. Progress in Brain Research, 2010, 182, 281-294.	1.4	28
224	Osteoporosis across chronic liver disease. Osteoporosis International, 2016, 27, 1967-1977.	3.1	28
225	Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers, 2019, 11, 1332.	3.7	28
226	Genderâ€related issues in the pharmacology of new antiâ€obesity drugs. Obesity Reviews, 2019, 20, 375-384.	6.5	28
227	Somatotropic Axis and Obesity: Is There Any Role for the Mediterranean Diet?. Nutrients, 2019, 11, 2228.	4.1	27
228	Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. Frontiers in Endocrinology, 2021, 12, 649496.	3.5	27
229	Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. Frontiers in Endocrinology, 2020, 11, 604341.	3.5	27
230	Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case–control study. Journal of Endocrinological Investigation, 2022, 45, 849-857.	3.3	27
231	Prolactin and Prostate Hypertrophy: A Pilot Observational, Prospective, Case-Control Study in Men with Prolactinoma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2770-2775.	3.6	26
232	CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget, 2016, 7, 18865-18875.	1.8	26
233	Low 25 (OH) vitamin D levels are associated with autoimmune thyroid disease in polycystic ovary syndrome. Endocrine, 2016, 53, 538-542.	2.3	26
234	Gut: A key player in the pathogenesis of type 2 diabetes?. Critical Reviews in Food Science and Nutrition, 2018, 58, 1294-1309.	10.3	26

#	Article	IF	CITATIONS
235	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine, 2020, 69, 441-450.	2.3	26
236	Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry. European Journal of Preventive Cardiology, 2021, 28, 1691-1700.	1.8	26
237	VLCKD: a real time safety study in obesity. Journal of Translational Medicine, 2022, 20, 23.	4.4	26
238	Dietary Recommendations for Post-COVID-19 Syndrome. Nutrients, 2022, 14, 1305.	4.1	26
239	Cardiovascular complications in acromegaly: methods of assessment. Pituitary, 2001, 4, 251-257.	2.9	25
240	Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clinical Endocrinology, 2005, 63, 342-349.	2.4	25
241	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. Endocrine-Related Cancer, 2014, 21, 601-613.	3.1	25
242	A novel heterozygous SOX2 mutation causing congenital bilateral anophthalmia, hypogonadotropic hypogonadism and growth hormone deficiency. Gene, 2014, 534, 282-285.	2.2	25
243	Therapeutic sequences in patients with grade 1â^'2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine, 2019, 66, 417-424.	2.3	25
244	Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 599-612.	5.7	25
245	The Growth Hormone (GH) Response to the Arginine Plus GH-Releasing Hormone Test Is Correlated to the Severity of Lipid Profile Abnormalities in Adult Patients with GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1277-1282.	3.6	25
246	The role of insulin-like growth factor system in the adrenocortical tumors. Minerva Endocrinologica, 2018, 44, 43-57.	1.8	25
247	Impairment of Bone Status in Patients with Central Diabetes Insipidus*. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2275-2280.	3.6	24
248	Are patients with acromegaly at high risk for dysrhythmias?. Clinical Endocrinology, 2001, 55, 305-306.	2.4	24
249	Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements. International Journal of Obesity Supplements, 2019, 9, 32-49.	12.6	24
250	Mediterranean diet as tool to manage obesity in menopause: A narrative review. Nutrition, 2020, 79-80, 110991.	2.4	24
251	The opera prevention project. International Journal of Food Sciences and Nutrition, 2021, 72, 1-3.	2.8	24
252	Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel. Endocrine, 2021, 72, 597-603.	2.3	24

#	Article	IF	Citations
253	Coffee consumption, health benefits and side effects: a narrative review and update for dietitians and nutritionists. Critical Reviews in Food Science and Nutrition, 2023, 63, 1238-1261.	10.3	24
254	Clinico–pathological features, treatments and survival of malignant insulinomas: a multicenter study. European Journal of Endocrinology, 2020, 182, 439-446.	3.7	24
255	New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. Minerva Endocrinologica, 2020, 45, 127-137.	1.8	24
256	Prognostic role of the <i><scp>CDNK</scp>1B</i> V109G polymorphism in multiple endocrine neoplasia type 1. Journal of Cellular and Molecular Medicine, 2015, 19, 1735-1741.	3.6	23
257	Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2555.	3.6	23
258	Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. Bone, 2016, 86, 79-85.	2.9	23
259	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. Calcified Tissue International, 2018, 103, 151-163.	3.1	23
260	COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess. Lancet Diabetes and Endocrinology, the, 2020, 8, 654-656.	11.4	23
261	Nutritional guidelines for the management of insulin resistance. Critical Reviews in Food Science and Nutrition, 2022, 62, 6947-6960.	10.3	23
262	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1986-1991.	3.6	23
263	Body fat in men with prolactinoma. Journal of Endocrinological Investigation, 2008, 31, 985-990.	3.3	22
264	Selenium supplementation modulates apoptotic processes in thyroid follicular cells. BioFactors, 2017, 43, 415-423.	5.4	22
265	The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?. Endocrine, 2018, 60, 15-27.	2.3	22
266	Pancreatic Neuroendocrine Neoplasms: Does Sex Matter?. Trends in Endocrinology and Metabolism, 2020, 31, 631-641.	7.1	22
267	Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk. Current Vascular Pharmacology, 2019, 17, 610-617.	1.7	22
268	Phase angle as an easy diagnostic tool for the nutritionist in the evaluation of inflammatory changes during the active stage of a very low-calorie ketogenic diet. International Journal of Obesity, 2022, 46, 1591-1597.	3.4	22
269	Lymphocyte subset pattern in acromegaly. Journal of Endocrinological Investigation, 2002, 25, 125-128.	3.3	21
270	Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing's disease. Journal of Endocrinological Investigation, 2002, 25, 142-151.	3.3	21

#	Article	IF	CITATIONS
271	Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation. Orphanet Journal of Rare Diseases, 2015, 10, 91.	2.7	21
272	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. Endocrine, 2018, 62, 215-233.	2.3	21
273	Phase Angle: Could Be an Easy Tool to Detect Low-Grade Systemic Inflammation in Adults Affected by Prader–Willi Syndrome?. Nutrients, 2020, 12, 2065.	4.1	21
274	Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e316-e327.	3.6	21
275	Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health. Journal of Endocrinological Investigation, 2021, 44, 2845-2847.	3.3	21
276	In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. Journal of Endocrinological Investigation, 2001, 24, 522-528.	3.3	20
277	A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients. Journal of Endocrinological Investigation, 2007, 30, 497-506.	3.3	20
278	Early Vascular Alterations in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3174-3179.	3.6	20
279	The impact of vitamin D deficiency on patients undergoing kidney transplantation: focus on cardiovascular, metabolic, and endocrine outcomes. Endocrine, 2015, 50, 568-574.	2.3	19
280	Irritable bowel syndrome: a new therapeutic target when treating obesity?. Hormones, 2019, 18, 395-399.	1.9	19
281	Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. Journal of Clinical Medicine, 2021, 10, 88.	2.4	19
282	The acromegalic arthropathy. Journal of Endocrinological Investigation, 2005, 28, 24-31.	3.3	19
283	The role of melatonin in the molecular mechanisms underlying metaflammation and infections in obesity: A narrative review. Obesity Reviews, 2022, 23, e13390.	6.5	18
284	Insulin-Mediated Diseases: Adrenal Mass and Polycystic Ovary Syndrome. Trends in Endocrinology and Metabolism, 2015, 26, 512-514.	7.1	17
285	Improving sleep disturbances in obesity by nutritional strategies: review of current evidence and practical guide. International Journal of Food Sciences and Nutrition, 2021, 72, 579-591.	2.8	17
286	Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy. Journal of Clinical Medicine, 2020, 9, 3507.	2.4	17
287	Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature. Journal of Endocrinological Investigation, 2020, 43, 1429-1445.	3.3	17
288	Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. Nutrients, 2020, 12, 1021.	4.1	17

#	Article	IF	Citations
289	Recombinant Growth Hormone (GH) Therapy in GH-Deficient Adults: A Long-Term Controlled Study on Daily Versus Thrice Weekly Injections. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3720-3725.	3.6	17
290	Could very low-calorie ketogenic diets turn off low grade inflammation in obesity? Emerging evidence. Critical Reviews in Food Science and Nutrition, 2023, 63, 8320-8336.	10.3	17
291	Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. European Journal of Endocrinology, 2000, 143, 61-69.	3.7	16
292	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. Endocrine, 2018, 61, 118-124.	2.3	16
293	The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. Endocrine, 2018, 62, 46-56.	2.3	16
294	Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?. World Neurosurgery, 2019, 127, 695-709.	1.3	16
295	Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature. Oncologist, 2016, 21, 875-886.	3.7	15
296	Vitamin-D status and mineral metabolism in two ethnic populations with sarcoidosis. Journal of Investigative Medicine, 2016, 64, 1025-1034.	1.6	15
297	Heavy Environmental Pressure in Campania and Other Italian Regions: A Short Review of Available Evidence. International Journal of Environmental Research and Public Health, 2018, 15, 105.	2.6	15
298	Sleep disturbances: one of the culprits of obesity-related cardiovascular risk?. International Journal of Obesity Supplements, 2020, 10, 62-72.	12.6	15
299	Mediterranean diet and breast cancer risk: a narrative review. Minerva Endocrinology, 2020, , .	1.1	15
300	Muscle Sympathetic Nerve Activity in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3203-3207.	3.6	14
301	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1209-1224.	2.5	14
302	Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study. Neuroendocrinology, 2018, 106, 264-273.	2.5	14
303	PRRT: identikit of the perfect patient. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 563-579.	5.7	14
304	Phase angle and Mediterranean diet in patients with acne: Two easy tools for assessing the clinical severity of disease. Journal of Translational Medicine, 2021, 19, 171.	4.4	14
305	Sarcopenic obesity: What about in the cancer setting?. Nutrition, 2022, 98, 111624.	2.4	14
306	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. Clinical Endocrinology, 1998, 49, 77-84.	2.4	13

#	Article	IF	Citations
307	5 Long-term acromegaly and associated cardiovascular complications: a case-based review. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, S31-S38.	4.7	13
308	Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance. Endocrinology, 2017, 158, 1527-1532.	2.8	13
309	Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. Journal of Endocrinological Investigation, 2017, 40, 1373-1380.	3.3	13
310	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. Journal of Cancer Research and Clinical Oncology, 2019, 145, 429-443.	2.5	13
311	From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 511-525.	5.7	13
312	Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature. Journal of Endocrinological Investigation, 2021, 44, 957-968.	3.3	13
313	Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?. Frontiers in Endocrinology, 2021, 12, 667784.	3.5	13
314	Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches. Frontiers in Endocrinology, 2021, 12, 651438.	3.5	13
315	Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?. Journal of Translational Medicine, 2021, 19, 324.	4.4	13
316	Specific cut-off for the 25-OH vitamin D levels to predict the highest Body Mass Index and fat mass: a sex-related analysis in obese patients. Minerva Endocrinologica, 2020, 45, 266-268.	1.8	13
317	Is there a relationship between the ketogenic diet and sleep disorders?. International Journal of Food Sciences and Nutrition, 2022, 73, 285-295.	2.8	13
318	Quality of life in patients with Cushing's disease: a modern approach. Clinical Endocrinology, 2012, 76, 776-777.	2.4	12
319	Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. Journal of Endocrinological Investigation, 2015, 38, 1099-1109.	3.3	12
320	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. Digestive and Liver Disease, 2021, 53, 367-374.	0.9	12
321	Severe systemic complications of acromegaly. Journal of Endocrinological Investigation, 2005, 28, 65-77.	3.3	12
322	Low-grade inflammation, CoVID-19, and obesity: clinical aspect and molecular insights in childhood and adulthood. International Journal of Obesity, 2022, 46, 1254-1261.	3.4	12
323	Clinical and nutritional management of very-low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: a practical guide for the nutritionist. Critical Reviews in Food Science and Nutrition, 2023, 63, 10775-10791.	10.3	12
324	Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease. Clinical Endocrinology, 1996, 45, 157-166.	2.4	11

#	Article	IF	Citations
325	Very delayed hyponatremia after surgery and radiotherapy for a pituitary macroadenoma. Journal of Endocrinological Investigation, 2002, 25, 163-168.	3.3	11
326	Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. Clinical Endocrinology, 2013, 79, 211-216.	2.4	11
327	Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. Annals of Nuclear Medicine, 2016, 30, 234-241.	2.2	11
328	<p>Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy</p> . ClinicoEconomics and Outcomes Research, 2019, Volume 11, 525-537.	1.9	11
329	The flavor test is a sensitive tool in identifying the flavor sensorineural dysfunction in Parkinson's disease. Neurological Sciences, 2019, 40, 1351-1356.	1.9	11
330	Could hop-derived bitter compounds improve glucose homeostasis by stimulating the secretion of GLP-1?. Critical Reviews in Food Science and Nutrition, 2019, 59, 528-535.	10.3	11
331	Maternal obesity: focus on offspring cardiometabolic outcomes. International Journal of Obesity Supplements, 2020, 10, 27-34.	12.6	11
332	Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. Frontiers in Oncology, 2020, 10, 1047.	2.8	11
333	A practical nutritional guide for the management of sleep disturbances in menopause. International Journal of Food Sciences and Nutrition, 2021, 72, 432-446.	2.8	11
334	Association of the Chronotype Score with Circulating Trimethylamine N-Oxide (TMAO) Concentrations. Nutrients, 2021, 13, 1671.	4.1	11
335	Nutritional management of type 2 diabetes in subjects with obesity: an international guideline for clinical practice. Critical Reviews in Food Science and Nutrition, 2023, 63, 2873-2885.	10.3	11
336	The clock diet: a practical nutritional guide to manage obesity through chrononutrition. Minerva Medica, 2022, 113, .	0.9	11
337	Chronotype: A Tool to Screen Eating Habits in Polycystic Ovary Syndrome?. Nutrients, 2022, 14, 955.	4.1	11
338	Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Review of Endocrinology and Metabolism, 2022, 17, 389-403.	2.4	11
339	Fibrous Variant of Hashimoto's Thyroiditis as a Diagnostic Pitfall in Thyroid Pathology. Case Reports in Endocrinology, 2013, 2013, 1-5.	0.4	10
340	Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. Endocrine, 2017, 57, 539-543.	2.3	10
341	Taste and the Gastrointestinal tract: from physiology to potential therapeutic target for obesity. International Journal of Obesity Supplements, 2019, 9, 1-9.	12.6	10
342	Health-care inequalities in Italy: challenges for the Government. Lancet Public Health, The, 2019, 4, e605.	10.0	10

#	Article	IF	Citations
343	COVID-19: Time for Post-Exposure Prophylaxis?. International Journal of Environmental Research and Public Health, 2020, 17, 3997.	2.6	10
344	Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. Endokrynologia Polska, 2019, 70, 305-312.	1.0	10
345	From the Ketogenic Diet to the Mediterranean Diet: The Potential Dietary Therapy in Patients with Obesity after CoVID-19 Infection (Post CoVID Syndrome). Current Obesity Reports, 2022, , .	8.4	10
346	"Planeterranean―Diet: extending worldwide the health benefits of Mediterranean Diet based on nutritional properties of locally available foods. Journal of Translational Medicine, 2022, 20, 232.	4.4	10
347	Cardiovascular Effects of Growth Hormone Treatment: Potential Risks and Benefits. Hormone Research in Paediatrics, 2004, 62, 42-50.	1.8	9
348	Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications. Critical Reviews in Oncology/Hematology, 2020, 146, 102840.	4.4	9
349	Ketogenic diet: a tool for the management of neuroendocrine neoplasms?. Critical Reviews in Food Science and Nutrition, 2022, 62, 1035-1045.	10.3	9
350	The Sun's Vitamin in Adult Patients Affected by Prader–Willi Syndrome. Nutrients, 2020, 12, 1132.	4.1	9
351	Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers. Frontiers in Endocrinology, 2021, 12, 665698.	3.5	9
352	Diet as a possible influencing factor in thyroid cancer incidence: the point of view of the nutritionist. Panminerva Medica, 2021, 63, 349-360.	0.8	9
353	Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. European Journal of Endocrinology, 2000, 143 Suppl 1, S35-S42.	3.7	8
354	Growth Hormone/Insulin-Like Growth Factor–I System and Connective Tissues: Basic Aspects and Clinical Implications. Rheumatic Disease Clinics of North America, 2005, 31, 29-42.	1.9	8
355	Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. Clinical Endocrinology, 2011, 74, 234-240.	2.4	8
356	NutriLive: An Integrated Nutritional Approach as a Sustainable Tool to Prevent Malnutrition in Older People and Promote Active and Healthy Ageing—The EIP-AHA Nutrition Action Group. Advances in Public Health, 2016, 2016, 1-9.	1.5	8
357	Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family. Journal of Clinical Medicine, 2020, 9, 588.	2.4	8
358	Association of Trimethylamine N-Oxide (TMAO) with the Clinical Severity of Hidradenitis Suppurativa (Acne Inversa). Nutrients, 2021, 13, 1997.	4.1	8
359	Cushing, acromegaly, GH deficiency and tendons. Muscles, Ligaments and Tendons Journal, 2014, 4, 329-32.	0.3	8
360	Canine insulinoma as a model for human malignant insulinoma research: Novel perspectives for translational clinical studies. Translational Oncology, 2022, 15, 101269.	3.7	8

#	Article	IF	Citations
361	Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment. Frontiers in Endocrinology, 2021, 12, 769744.	3.5	8
362	Prognostic significance of laterality in lung neuroendocrine tumors. Endocrine, 2022, 76, 733-746.	2.3	8
363	Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients. Gynecological Endocrinology, 1995, 9, 15-21.	1.7	7
364	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. Clinical Endocrinology, 2001, 54, 97-106.	2.4	7
365	99m Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. Clinical Endocrinology, 2002, 56, 713-721.	2.4	7
366	Aortic root ectasia in patients with acromegaly: an emerging complication*. Clinical Endocrinology, 2011, 75, 420-421.	2.4	7
367	Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. Endocrine, 2015, 50, 824-825.	2.3	7
368	Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications. Frontiers in Endocrinology, 2021, 12, 665631.	3.5	7
369	Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. European Journal of Endocrinology, 2022, 186, K17-K24.	3.7	7
370	Adherence to the Mediterranean Diet as a Modifiable Risk Factor for Thyroid Nodular Disease and Thyroid Cancer: Results From a Pilot Study. Frontiers in Nutrition, 0, 9, .	3.7	7
371	Dose optimization of somatostatin analogues for acromegaly patients. Journal of Endocrinological Investigation, 2010, 33, 125-127.	3.3	6
372	Low 25-Hydroxyvitamin D Levels and Low Bone Density Assessed by Quantitative Ultrasonometry in a Cohort of Postmenopausal Italian Nuns. Journal of Clinical Densitometry, 2013, 16, 308-312.	1.2	6
373	Vitamin D Fortification of Consumption Cow's Milk: Health, Nutritional and Technological Aspects. A Multidisciplinary Lecture of the Recent Scientific Evidence. Molecules, 2021, 26, 5289.	3.8	6
374	Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. Endocrine, 2022, 75, 623-634.	2.3	6
375	Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. Journal of Endocrinological Investigation, 2022, 45, 941-961.	3.3	6
376	Mediterranean Diet: What Are the Consequences for Menopause?. Frontiers in Endocrinology, 2022, 13, 886824.	3.5	6
377	Influence of Growth Hormone on Cardiovascular Health and Disease. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2003, 2, 347-356.	1.8	5
378	Hashimoto's Thyroiditis and Entero-Chromaffin-like Cell Hyperplasia: Early Detection and Somatostatin Analogue Treatment. European Journal of Inflammation, 2013, 11, 863-870.	0.5	5

#	Article	IF	Citations
379	Pituitary function and morphology in Fabry disease. Endocrine, 2015, 50, 483-488.	2.3	5
380	Advances in therapy of adenomas secreting GH, ACTH and TSH. Nature Reviews Endocrinology, 2015, 11, 73-74.	9.6	5
381	Long-term safety and efficacy of Omnitrope $\hat{A}^{\odot}$ in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. Journal of Endocrinological Investigation, 2017, 40, 669-678.	3.3	5
382	Accuracy of Fine Needle Cytology in Histological Prediction of Papillary Thyroid Carcinoma Variants: a Prospective Study. Endocrine Pathology, 2017, 28, 187-197.	9.0	5
383	Pancreatic Neuroendocrine Tumors in patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences. Neuroendocrinology, 2020, 111, 696-704.	2.5	5
384	Characterization with hybrid imaging of cystic pheochromocytomas: correlation with pathology. Quantitative Imaging in Medicine and Surgery, 2021, 11, 862-869.	2.0	5
385	Papillary thyroid carcinoma arising in ectopic thyroid tissue within sternocleidomastoid muscle: a review of current literature. Minerva Endocrinologica, 2021, 45, 318-325.	1.8	5
386	Bone metabolism, bone mass and structural integrity profile in professional male football players. Journal of Sports Medicine and Physical Fitness, 2020, 60, 912-918.	0.7	5
387	"Forever young at the table― metabolic effects of eating speed in obesity. Journal of Translational Medicine, 2021, 19, 530.	4.4	5
388	The treatment algorithm of acromegaly. Journal of Endocrinological Investigation, 2003, 26, 39-45.	3.3	5
389	Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?. Journal of Clinical Medicine, 2022, 11, 1019.	2.4	5
390	Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration. Journal of Endocrinological Investigation, 1998, 21, 257-262.	3.3	4
391	Polycystic Ovary Syndrome and Hepatic Steatosis: Could Low-Grade Chronic Inflammation Be Mediated by the Spleen?. European Journal of Inflammation, 2013, 11, 179-191.	0.5	4
392	Hospitalizations in Pediatric and Adult Patients for All Cancer Type in Italy: The EPIKIT Study under the E.U. COHEIRS Project on Environment and Health. International Journal of Environmental Research and Public Health, 2017, 14, 495.	2.6	4
393	Diagnosis of Flier's syndrome in a patient with nondiabetic hypoglycemia: a case report and critical appraisal of the literature. Endocrine, 2020, 69, 73-78.	2.3	4
394	What about Mediterranean diet as tool to improve sleep quality in obesity?. Minerva Endocrinology, 2021, , .	1.1	4
395	Hyperprolactinemia after menopause: Diagnosis and management. Maturitas, 2021, 151, 36-40.	2.4	4
396	Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia. European Journal of Endocrinology, 2021, 185, 475-484.	3.7	4

#	Article	IF	Citations
397	The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. Journal of Endocrinological Investigation, 2003, 26, 53-6.	3.3	4
398	The importance of presurgical somatostatin analogue therapy in acromegaly. Endokrynologia Polska, 2007, 58, 356-60.	1.0	4
399	Insulin-like growth factor-1 (IGF-1) as predictor of cardiovascular mortality in heart failure patients: data from the T.O.S.CA. registry. Internal and Emergency Medicine, 2022, 17, 1651-1660.	2.0	4
400	Complete clinical and biochemical control with cabergoline and octreotide in a patient with ectopic ACTH syndrome before surgery. Journal of Endocrinological Investigation, 2015, 38, 373-374.	3.3	3
401	Comment on  Acne and nutrition: hypotheses, myths and facts'. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e418-e419.	2.4	3
402	Cut-off for the Mediterranean diet score to identify subjects with morning chronotype in middle-aged Italian adults. Minerva Endocrinology, 2022, 47, .	1.1	3
403	Letter to the Editor: Vitamin D: A Wonder Drug for the Cure of Type 2 Diabetes?. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L43-L44.	3.6	3
404	Gestational obesity: An unconventional endocrine disruptor for the fetus. Biochemical Pharmacology, 2022, 198, 114974.	4.4	3
405	Pasireotide for the treatment of Cushing's disease. Expert Opinion on Orphan Drugs, 2013, 1, 557-567.	0.8	2
406	Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. Frontiers in Endocrinology, 2021, 12, 700806.	3.5	2
407	The role of the nurse in the Obesity Clinic: a practical guideline. Panminerva Medica, 2021, 63, .	0.8	2
408	Craniopharyngioma, Chronotypes and Metabolic Risk Profile. Nutrients, 2021, 13, 3444.	4.1	2
409	Multifocality and Hashimoto's thyroiditis as independent predictors of structural recurrence in a cohort of low risk intrathyroidal papillary thyroid cancer Journal of Clinical Oncology, 2017, 35, e17577-e17577.	1.6	2
410	SAT-259 Natural History of Anthropometric Parametres of Obesity in Children Affected by X-Linked Hypophosphatemia: Longitudinal Obserbational Study. Journal of the Endocrine Society, 2019, 3, .	0.2	2
411	New perspectives in the medical treatment of acromegaly. Journal of Endocrinological Investigation, 2005, 28, 58-66.	3.3	2
412	Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements. Journal of Biological Regulators and Homeostatic Agents, 2014, 28, 733-41.	0.7	2
413	Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease. Pituitary, 2001, 4, 187-193.	2.9	1
414	Diabetes and Cancer. Frontiers in Endocrinology, 2011, 2, 22.	3.5	1

#	Article	IF	Citations
415	Diabetes and Obesity as Independent Risk Factors for Osteoporosis in Postmenopausal Women: A Population Study. European Journal of Inflammation, 2014, 12, 479-487.	0.5	1
416	Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score. Alimentary Pharmacology and Therapeutics, 2015, 42, 1033-1034.	3.7	1
417	Comment on Krul-Poel et al. Effect of Vitamin D Supplementation on Glycemic Control in Patients With Type 2 Diabetes (SUNNY Trial): A Randomized Placebo-Controlled Trial. Diabetes Care 2015;38:1420–1426. Diabetes Care, 2015, 38, e190-e190.	8.6	1
418	Italian university rectors for health and environment: the U4ALL initiative. Lancet, The, 2019, 394, 1319.	13.7	1
419	Editorial: Health-Related Complications of Acromegaly. Frontiers in Endocrinology, 2020, 11, 496.	3.5	1
420	Editorialâ€"Special Issue: Foreword to the Special Issue on NIKE: Neuroendocrine Tumors, Innovation in Knowledge and Education. Frontiers in Endocrinology, 2021, 12, 722145.	3.5	1
421	Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience. Frontiers in Neurology, 2022, 13, 783737.	2.4	1
422	A practical nutritional guideline to manage neuroendocrine neoplasms through chronotype and sleep. Critical Reviews in Food Science and Nutrition, 2023, 63, 7546-7563.	10.3	1
423	Updating obesity management strategies: an audit of Italian specialists. Eating and Weight Disorders, 2022, 27, 2653-2663.	2.5	1
424	Prognostic Effect of Lymph Node Metastases and Mesenteric Deposits in Neuroendocrine Tumors of the Small Bowel. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 3209-3221.	3.6	1
425	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. Journal of Urology, 1998, 160, 1583-1584.	0.4	0
426	The accuracy of the arginine growth hormone test in Parkinsonism. Movement Disorders, 2008, 23, 1331-1331.	3.9	0
427	Hormonal and seminal evaluation of Leydig cell tumour patients before and after orchiectomy. Andrologia, 2000, 32, 147-154.	2.1	0
428	Frontiers in Cancer Endocrinology. Frontiers in Endocrinology, 2011, 2, 7.	3.5	0
429	LO2 Insulin sensitivity and early-phase insulin secretion in normoglycemic patients with huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A43.4-A44.	1.9	0
430	Reply to the Letter of Terracini B. et al. "Comment on Piscitelli et al. Hospitalizations in Pediatric and Adult Patients for All Cancer Type in Italy: The EPIKIT Study under the E.U. COHEIRS Project on Environment and Health― Int. J. Environ. Res. Public Health 2017, 14, 495. International Journal of Environmental Research and Public Health, 2017, 14, 1291.	2.6	0
431	Treatment of Paget's disease of the bone: long-term effect of neridronate in a real-life setting. Minerva Endocrinology, 2022, 46, 374-383.	1.1	0
432	Is the impact of GH deficiency on the heart dependent on time of onset?. International Journal of Clinical Practice, Supplement, 2002, , 27-31.	0.3	0

#	Article	IF	CITATIONS
433	An unusual case report of polycystic ovary syndrome. Journal of Endocrinological Investigation, 2022, , 1.	3.3	0